The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Achieving longer remissions with venetoclax monotherapy in R/R CLL
Venetoclax monotherapy has been shown to extend progression-free survival (PFS) in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. In a post-hoc analysis of different trials, William Wierda, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, and colleagues, have looked at the link between PFS and depth of response in two patient cohorts receiving venetoclax monotherapy in the relapsed/refractory setting. In this interview, Prof Wierda explores the results presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
